Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loperamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 1.00 |
| ▸ | DRD4 | P21917 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loperamide SCHEMBL12387663 | 1.00 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL8409779 | 1.00 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL8409268 | 0.99 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL21327979 | 0.99 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL15048 | 0.99 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL9068543 | 0.99 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL2346867 | 0.98 | OPRM1 (0.98) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL542589 | 0.98 | OPRM1 (0.96) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL5084617 | 0.97 | OPRM1 (0.94) | OPRM1DRD4ADRA2ASLC6A4DRD2 | |
| Loperamide SCHEMBL12470757 | 0.96 | OPRM1 (0.92) | OPRM1DRD4ADRA2ASLC6A4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 24797 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4719179-A2 | MANUFACTURING METHODS FOR GASTRIC RESIDENCE SYSTEMS | Nortiva Bio, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-12582601-B2 | Orodispersible powder composition | BIOPHARMA SYNERGIES, S.L. (ES) | 2026-03-24 | — | — | US | claimed |
| EP-4705511-A1 | DNA METHYLATION-BASED ALGORITHM TO DIAGNOSE IRRITABLE BOWEL SYNDROME AND OTHER GI CONDITIONS | The Regents of the University of California (US) | 2026-03-11 | — | — | EP | claimed |
| US-12571795-B2 | Anti-MAA immunoglobulin isotypes in inflammatory bowel disease: novel diagnostic implications for ulcerative colitis | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2026-03-10 | — | — | US | claimed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-0428296-A2 | Pharmaceutical compositions for treating gastrointestinal distress | McNEIL-PPC, INC. (US) | 1991-05-22 | — | — | EP | claimed |
| US-5004613-A | Wet Granulation Process Using Hydroxyethyl Cellulose And Polyvinylpyrrolidone | MCNEIL-PPC, INC. (US) | 1991-04-02 | — | — | US | claimed |
| EP-0411952-A2 | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | McNEIL-PPC, INC. (US) | 1991-02-06 | — | — | EP | claimed |
| EP-0393909-A1 | Composition | Beecham Group p.l.c. (GB) | 1990-10-24 | — | — | EP | claimed |
| EP-0219898-B1 | NOVEL ALPHA,ALPHA-DIARYL-4-ARYL-4-HYDROXY-1-PIPERIDINEBUTANAMIDE, N-OXIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-05-23 | — | — | EP | claimed |
| US-4892735-A | Platinum chemotherapeutic product | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1990-01-09 | — | — | US | claimed |
| EP-0339772-A1 | Platinum chemotherapeutic product | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1989-11-02 | — | — | EP | claimed |
| US-4824853-A | α,α-diaryl-4-aryl-4-hydroxy-1-piperidinebutanamide, N-oxides and method of treating diarrhea | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-04-25 | — | — | US | claimed |
| EP-0293432-A1 | ORGANIC ACID ANHYDRIDE AND PHARMACEUTICAL COMPOSITION ON A PRODRUG BASE | NV GANTAX PHARMACEUTICA (BE) | 1988-12-07 | — | — | EP | claimed |
| WO-1988003020-A1 | ORGANIC ACID ANHYDRIDE AND PHARMACEUTICAL COMPOSITION ON A PRODRUG BASE | NV GANTAX PHARMACEUTICA (BE) | 1988-05-05 | — | — | WO | claimed |